The Cigna Group is a global health services company incorporated in Delaware in 1981, headquartered in Bloomfield, Connecticut. The company operates through two primary segments: Evernorth Health Services (pharmacy benefit services, specialty pharmacy, and care management) and Cigna Healthcare (U.S. and International medical benefits). As of the latest reporting, Cigna employs approximately 67,700 people and maintains relationships with over 185 million customers globally. Its dual-engine model integrates pharmacy supply-chain expertise with medical benefit management, positioning it as a massive, integrated player in the U.S. healthcare ecosystem.


2. Executive Summary

Cigna’s 2026 performance reveals a company in deliberate transition. While 9M 2026 revenue grew 5.6% to $213.8 billion**, profitability faced severe pressure in the third quarter. **Q3 2026 Shareholders’ Net Income fell 22.8% to $1.44 billion (Diluted EPS $5.47), driven by medical cost inflation and a higher tax rate. However, **adjusted EPS of $7.98 beat consensus**, and management raised full-year 2026 adjusted EPS guidance to at least $30.60 .

The balance sheet remains robust with **$43.4 billion in equity** and a debt-to-capitalization ratio of approximately 41.8%, moving toward management’s ~40% target. Operating cash flow declined 5% to $3.28 billion for the nine months, largely due to a $2.77 billion build in accounts receivable. The company continues to return capital, repurchasing $531 million in stock during 9M 2026 and paying $1.24 billion in dividends. Management has explicitly characterized 2026 and 2027 as “transitional years” for the Pharmacy Benefit Services business, with a return to growth expected by 2028 .

Market Snapshot (as of November 16, 2026): Stock Price $300.16**; Period Return (YTD) **+7.54%**; Market Cap **$79.09B; Forward PE 9.22x; Dividend Yield 2.08%; Analyst Consensus Buy; Average Price Target $344.04 (+14.62% upside) .



3. The Cigna Group — Consolidated Statement of Income (FY2025 vs. FY2024)

Source: The Cigna Group Form 10-K for fiscal year ended December 31, 2025 (filed February 26, 2026), Consolidated Statement of Income

Line Item (USD millions)FY2025FY2024Change ($)Change (%)
REVENUES
Premiums$40,261$45,996−$5,735−12.5%
Fees and other revenues$233,593$200,152+$33,441+16.7%
Net investment income$1,046$973+$73+7.5%
TOTAL REVENUES$274,900$247,121+$27,779+11.2%
BENEFITS AND EXPENSES
Pharmacy and other service costs$214,991$182,509+$32,482+17.8%
Medical costs and other benefit expenses$34,349$38,648−$4,299−11.1%
Selling, general and administrative expenses$14,617$14,844−$227−1.5%
Amortization of acquired intangible assets$1,743$1,703+$40+2.3%
TOTAL BENEFITS AND EXPENSES$265,700$237,704+$27,996+11.8%
Income from operations$9,200$9,417−$217−2.3%
Interest expense and other$(1,408)$(1,435)+$27—
Net gain on sale of businesses$13$24−$11—
Net investment losses$(24)$(2,737)+$2,713—
Income before income taxes$7,781$5,269+$2,512+47.7%
Total income taxes$1,493$1,491+$2+0.1%
Net income$6,288$3,778+$2,510+66.4%
Less: Net income attributable to noncontrolling interests$331$344−$13—
Shareholders’ Net Income$5,957$3,434+$2,523+73.5%
Earnings per share
Basic$22.33$12.25+$10.08+82.3%
Diluted$22.18$12.12+$10.06+83.0%

Key Observations from the Income Statement

1. Revenue growth was driven entirely by Evernorth, not Cigna Healthcare.
Total revenues rose 11.2%, but this was powered by Fees and other revenues (+16.7%), which reflects Evernorth’s pharmacy benefit and specialty services. Meanwhile, Premiums fell 12.5% to $40.3 billion, confirming the structural decline in Cigna Healthcare’s insured medical business—exacerbated by the HCSC divestiture completed in March 2025 .

2. Operating income declined despite revenue growth.
Income from operations fell 2.3% to $9.2 billion. The culprit is visible in the expense lines: Pharmacy and other service costs surged 17.8%, outpacing the 16.7% growth in fees. This compressed margins in the Evernorth segment. Medical costs fell 11.1%, roughly tracking the premium decline.

3. The GAAP net income surge is a base-effect illusion.
Shareholders’ net income jumped 73.5% to $5.96 billion—but this was almost entirely due to the **absence of 2024’s massive net investment losses**. In FY2024, Cigna recorded $2.737 billion in net investment losses; in FY2025, that figure collapsed to just $24 million. The swing added roughly $2.7 billion to pretax income. Without this swing, operating performance actually deteriorated .

4. EPS growth is partly buyback-driven.
Diluted EPS rose 83% to $22.18, but the diluted share count fell from approximately 283 million to 269 million due to the $3.6 billion share repurchase program executed in 2025 . This provided a modest tailwind to per-share figures.

5. The effective tax rate normalized.
The tax provision was essentially flat at $1.49 billion, but because pretax income rose sharply, the effective rate fell to 19.2% from 28.3% in 2024. This flattered net income growth.


4. The Cigna Group — Consolidated Balance Sheets (FY2025 vs. FY2024)

Source: The Cigna Group Form 10-K for fiscal year ended December 31, 2025, Consolidated Balance Sheets (page 60). Data cross-verified across SEC filing extracts and LSEG/FT data .

Line Item (USD millions)Dec 31, 2025Dec 31, 2024Change ($)Change (%)
ASSETS
Current Assets
Cash and cash equivalents$7,676$7,550+$126+1.7%
Short-term investments$1,056$665+$391+58.8%
Cash and short-term investments$8,732$8,215+$517+6.3%
Accounts receivable, net$28,529$24,065+$4,464+18.5%
Other receivables$359$162+$197+121.6%
Total receivables, net$28,888$24,227+$4,661+19.2%
Inventories$7,338$6,692+$646+9.7%
Other current assets$2,856$9,736−$6,880−70.7%
Total current assets$47,814$48,870−$1,056−2.2%
Non-Current Assets
Property, plant and equipment, net$3,651$3,654−$3−0.1%
Goodwill$44,924$44,370+$554+1.2%
Other intangible assets, net$28,560$29,417−$857−2.9%
Long-term investments$18,471$15,128+$3,343+22.1%
Other long-term assets$14,499$14,442+$57+0.4%
Total non-current assets$110,105$107,011+$3,094+2.9%
TOTAL ASSETS$157,919$155,881+$2,038+1.3%
LIABILITIES
Current Liabilities
Accounts payable$10,659$9,294+$1,365+14.7%
Accrued expenses$9,048$9,387−$339−3.6%
Short-term debt / notes payable$592$3,035−$2,443−80.5%
Other current liabilities$36,043$36,263−$220−0.6%
Total current liabilities$56,342$57,979−$1,637−2.8%
Non-Current Liabilities
Long-term debt$30,871$28,937+$1,934+6.7%
Deferred income taxes$7,145$6,975+$170+2.4%
Other long-term liabilities$21,687$20,747+$940+4.5%
Total non-current liabilities$59,703$56,659+$3,044+5.4%
TOTAL LIABILITIES$116,045$114,638+$1,407+1.2%
SHAREHOLDERS‘ EQUITY
Common stock ($0.01 par)$4$4——
Additional paid-in capital$31,790$31,288+$502+1.6%
Retained earnings$47,865$43,519+$4,346+10.0%
Treasury stock, at cost$(35,140)$(31,437)−$3,703+11.8%
Accumulated other comprehensive loss$(2,806)$(2,341)−$465+19.9%
TOTAL SHAREHOLDERS’ EQUITY$41,713$41,033+$680+1.7%
TOTAL LIABILITIES AND EQUITY$157,919$155,881+$2,038+1.3%

Note: Minority interest of $161 million (2025) and $210 million (2024) is included in total liabilities per the FT/LSEG presentation . The SEC Schedule I extract shows total liabilities of $116,045M and total equity of $41,713M, which reconcile to the total assets figure .

Key Balance Sheet Observations

1. Receivables growth far outpaced revenue growth.
Total receivables rose 19.2% to $28.9 billion, while total revenues grew 11.2%. This divergence suggests either slower collections or a shift in revenue mix toward clients with longer payment cycles. For a company with Cigna’s scale, a $4.7 billion increase in receivables is material and warrants monitoring for any deterioration in collection quality.

2. Inventories grew 9.7%, roughly in line with pharmacy revenue.
The $7.3 billion inventory balance (brand and generic pharmaceuticals in home delivery and specialty pharmacies) increased modestly relative to the 16.7% growth in fees and other revenues. This is reasonable given the high-turnover nature of pharmaceutical inventory.

3. Short-term debt was dramatically reduced.
Cigna paid down **$2.4 billion** of short-term debt (notes payable and current portion of long-term debt), cutting the balance from $3.0 billion to $0.6 billion. This was likely funded by the $4.5 billion in new long-term debt issued during 2025, effectively terming out its debt maturity profile.

**4. Long-term debt increased by $1.9 billion.**
The company issued $4.46 billion in new long-term debt and repaid $3.86 billion, resulting in a net increase of approximately $600 million at the parent level, but the consolidated long-term debt balance rose $1.9 billion . The debt-to-capitalization ratio stands at approximately **43.0%** ($31.5B total debt / $73.2B total capitalization), a modest improvement from 43.8% at year-end 2024.

5. Treasury stock surged by $3.7 billion.**
The company repurchased **$3.62 billion
of common stock in 2025, continuing an aggressive capital return program that has reduced shares outstanding from 274 million to 263 million . This buyback provides EPS support but also reduces the equity base.

**6. Shareholders’ equity grew only 1.7% despite $5.96 billion in net income.**
The combination of $3.6 billion in buybacks and $465 million in other comprehensive losses (likely investment-related) consumed most of the year‘s earnings. Retained earnings rose $4.3 billion, but treasury stock absorbed $3.7 billion of that increase.


5. The Cigna Group — Consolidated Statements of Cash Flows (FY2025 vs. FY2024)

Source: The Cigna Group Form 10-K for fiscal year ended December 31, 2025 (filed February 26, 2026), Consolidated Statements of Cash Flows (page 62). Data cross-verified across FT/LSEG , Stock Analysis , and Sina Financial .

Line Item (USD millions)FY2025FY2024Change ($)Change (%)
CASH FLOWS FROM OPERATING ACTIVITIES
Net income$6,288$3,778+$2,510+66.4%
Depreciation and amortization$2,775$2,775$00.0%
Non-cash items (incl. investment losses)$11$2,713−$2,702−99.6%
Changes in working capital$201$1,192−$991−83.1%
Other operating adjustments (net)$326$(95)+$421—
Net cash provided by operating activities$9,601$10,363−$762−7.4%
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures$(1,212)$(1,406)+$194−13.8%
Cash acquisitions, net of cash acquired$(597)$(131)−$466+355.7%
Proceeds from divestitures$2,984$521+$2,463+472.7%
Investment in securities, net$(4,552)$(248)−$4,304+1,735%
Other investing activities, net$(1,030)$(838)−$192+22.9%
Net cash used in investing activities$(4,407)$(2,102)−$2,305+109.7%
CASH FLOWS FROM FINANCING ACTIVITIES
Net short-term debt repayments$(2,443)———
Proceeds from long-term debt issuance$6,457$4,400+$2,057+46.8%
Repayments of long-term debt$(4,681)$(3,340)−$1,341+40.1%
Repurchase of common stock$(3,418)$(6,729)+$3,311−49.2%
Dividends paid$(1,611)$(1,567)−$44+2.8%
Other financing activities, net$(725)$(411)−$314+76.4%
Net cash used in financing activities$(6,421)$(7,647)+$1,226−16.0%
NET CHANGE IN CASH
Effect of foreign exchange rates on cash$32$(20)+$52—
Net (decrease) increase in cash and cash equivalents$(1,195)$594−$1,789—
Cash and cash equivalents, beginning of year$8,931$8,337+$594+7.1%
Cash and cash equivalents, end of year$7,736$8,931−$1,195−13.4%
SUPPLEMENTAL DISCLOSURES
Cash taxes paid$399$898−$499−55.6%
Cash interest paid$1,350$1,342+$8+0.6%
Free cash flow (Operating CF − Capex)$8,389$8,957−$568−6.3%

Key Cash Flow Observations

1. Operating cash flow declined 7.4% despite net income rising 66%.
This is the most important takeaway from the cash flow statement. The $762 million decline in operating cash flow occurred because the prior year’s net income was depressed by non-cash investment losses ($2.7 billion), which were added back to operating cash flow in FY2024. In FY2025, those non-cash charges largely disappeared, so the “quality” of the operating cash flow comparison is distorted. Adjusted for non-cash items, Cigna’s core cash generation was roughly stable—a more reassuring picture than the headline decline suggests.

2. Working capital was a modest source of cash ($201 million), down sharply from $1.19 billion in FY2024.
The decline in working capital contribution reflects the $4.6 billion increase in accounts receivable** (noted in the balance sheet analysis) and a **$646 million increase in inventory, partially offset by a $4.7 billion increase in accounts payable. In plain terms, Cigna’s receivables grew faster than its payables, consuming cash that would otherwise have boosted operating cash flow.

**3. The HCSC divestiture generated $2.98 billion in proceeds.**
The sale of the Medicare Advantage and related businesses to HCSC closed in March 2025, contributing the bulk of the $2.98 billion in divestiture proceeds. Management stated that the majority of these proceeds were allocated to share repurchases . This explains why buybacks ($3.4 billion) exceeded what operating cash flow alone could comfortably fund after dividends.

4. Investment in securities surged to $4.55 billion, up from just $248 million.
This line item reflects net purchases of investment securities (bonds and other fixed-income instruments) held in Cigna’s insurance investment portfolios. The sharp increase suggests the company redeployed divestiture proceeds and operating cash into its investment portfolio, likely to support reserve requirements and match liabilities. This is a normal activity for an insurer but reduced reported investing cash flow.

**5. Free cash flow declined 6.3% to $8.39 billion.**
Free cash flow (operating cash flow minus capital expenditures) remains robust at $8.4 billion, comfortably covering the $1.6 billion in dividends paid. However, the decline from $8.96 billion in FY2024 is a reminder that Cigna’s cash generation, while strong, is not immune to working capital swings and the loss of earnings contribution from divested businesses.

6. Cash balance declined $1.2 billion to $7.74 billion.
The net decrease in cash reflects the aggressive capital return program ($3.4 billion buybacks + $1.6 billion dividends = $5.0 billion returned to shareholders) funded partly by the HCSC proceeds and partly by drawing down cash. Despite this decline, the year-end cash balance of $7.7 billion remains healthy for a company of Cigna’s scale and liquidity profile.

RatioCalculationResult
Operating Cash Flow RatioOperating CF / Current Liabilities$9,601 / $56,342 = 0.17x
Cash Flow per Share (Diluted)Operating CF / Diluted Shares$9,601 / 269M ≈ **$35.69**
Free Cash Flow Yield (at $274.70)FCF per Share / Share Price($8,389 / 269) / $274.70 = 11.3%
Capex as % of RevenueCapex / Revenue$1,212 / $274,900 = 0.44%
Dividend Payout Ratio (FCF basis)Dividends / Free Cash Flow$1,611 / $8,389 = 19.2%

Interpretation: Cigna’s free cash flow yield of 11.3% is exceptionally high for a large-cap healthcare company, reflecting the stock’s depressed valuation following the October 2025 MCR disclosure. The dividend payout ratio of 19.2% on a free cash flow basis is very conservative, leaving ample room for continued buybacks and dividend increases. The low capex intensity (0.44% of revenue) is typical for an insurer/PBM that does not require heavy physical infrastructure investment.

6. Audit Observations and Critical Audit Matters (Now Complete)

Source: PricewaterhouseCoopers LLP auditor’s report included in the FY2025 10-K . PwC has served as Cigna’s auditor since 1983.

6.1 Audit Opinion and Internal Control

PwC issued an unqualified opinion on both the consolidated financial statements and the effectiveness of internal control over financial reporting. The report states that the financial statements present fairly, in all material respects, the financial position of The Cigna Group as of December 31, 2025 .

No going-concern qualification was issued. Cigna’s $9.6 billion operating cash flow, $7.7 billion cash balance, and 43% debt-to-capitalization ratio support the conclusion that the company is financially viable on an ongoing basis.

6.2 The Single Critical Audit Matter (CAM)

PwC identified one Critical Audit Matter: the valuation of Incurred But Not Reported (IBNR) liabilities plus expected development on reported claims and reported claims in process for the Cigna Healthcare segment .

CAM ParameterDetail
IBNR Balance (Dec 31, 2025)$4.0 billion
Key AssumptionsCompletion factors and medical cost trend
Auditor JudgmentHigh degree of subjectivity; involved specialized actuaries
Auditor ProceduresIndependent estimate of IBNR range; evaluation of actuarial methodologies; consistency checks period-over-period

Why this matters for investors: The IBNR reserve is the single largest estimate on Cigna’s balance sheet that is subject to management judgment. A $4.0 billion reserve means that a **1% change in the completion factor assumption** could swing the reserve by approximately **$40 million**—directly impacting pretax income. Given the MCR deterioration observed in Q3 2025 (84.8% vs. 82.8%), the adequacy of this reserve is the most sensitive earnings variable for the Cigna Healthcare segment.

What-If Analysis: If PwC’s independent estimate had fallen outside management’s range, a reserve adjustment would have been required. No such adjustment was disclosed, meaning PwC concluded management’s $4.0 billion estimate was reasonable. However, the CAM disclosure itself signals that this is an area where future earnings surprises are most likely to originate.


7. Litigation: Current Position and Probable Impact

7.1 Nature of Legal Exposure

Cigna’s legal matters fall into five categories per the accounting policy disclosure:

  1. Ordinary course claims and lawsuits — routine litigation from managing a global health company
  2. Regulatory inquiries and audits — including state insurance department examinations
  3. Government investigations — including federal and state False Claims Act matters, both government-initiated and qui tam (whistleblower) actions filed under seal
  4. Subpoenas from governmental agencies — Cigna states it is cooperating with various subpoenas “arising in the normal course of its business”
  5. Disputed tax matters — IRS and state/foreign audits, accounted for under uncertain tax positions (Note 21)

7.2 Specific Litigation Disclosed

AI Claims Evaluation Litigation: The risk factors disclose that Cigna is currently subject to litigation claiming that it improperly used AI in claims evaluation . This is a material disclosure because:

  • It represents a new category of legal exposure (algorithmic decision-making)
  • Regulatory scrutiny of AI in healthcare is intensifying
  • If successful, the precedent could affect claims processing across the industry

Securities Investigation (October 2025): As previously noted, Levi & Korsinsky commenced an investigation following the Q3 2025 MCR disclosure. This is not disclosed in the 10-K Legal Matters section provided (which suggests it may not yet have matured into formal litigation as of the filing date).

Historical Litigation Charges: The 10-K special items table shows $(17) million in after-tax litigation benefits in 2025** for Cigna Healthcare, compared to **$171 million in after-tax charges in 2023 . This indicates that prior litigation reserves were partially released in 2025, a favorable development for the segment’s reported earnings.

7.3 What-If Analysis: Litigation Impact on Future Earnings

ScenarioProbable Pretax ImpactEPS Impact (after-tax)Probability Assessment
AI claims litigation settlement$50–200M$0.15–$0.60Moderate — early-stage, uncertain
False Claims Act resolution$100–500M$0.30–$1.50Low to moderate — no specific case disclosed
Securities class action (if filed)$50–150M$0.15–$0.45Moderate — investigation commenced
Routine litigation (aggregate)Already reservedMinimal incrementalHigh — ordinary course

Key Insight: The 10-K does not disclose any specific material litigation reserve or any single case that management believes would have a material adverse effect. The phrase “arising in the normal course of its business” is repeated throughout. However, the AI claims litigation is the most novel and potentially impactful exposure because it lacks precedent and could attract regulatory attention beyond the courtroom.


8. Comparative Financial Statements and Ratio Analysis

8.1 Income Statement Analysis (9M 2026 vs. 9M 2025)

Source: Q3 2026 10-Q Page 3 (All figures in USD Millions)

Line ItemQ3 2026Q3 2025Q3 % Change9M 20269M 20259M % ChangeFY2025 (Dec-2025) Position
Pharmacy revenues$58,982$56,054+5.2%$170,191$158,336+7.5%$216,414
Premiums$9,885$9,081+8.9%$29,556$30,973-4.6%$40,261
Fees and other revenues$4,529$4,380+3.4%$13,337$12,412+7.5%$17,179
Net investment income$287$233+23.2%$761$707+7.6%$1,046
TOTAL REVENUES$73,683$69,748+5.6%$213,845$202,428+5.6%$274,900
Pharmacy and other service costs$58,590$55,530+5.5%$169,393$157,196+7.8%$214,991
Medical costs and other benefit expenses$8,496$7,842+8.3%$24,850$26,089-4.7%$34,349
Selling, general and administrative$3,612$3,362+7.4%$10,804$11,008-1.9%$14,617
Amortization of acquired intangibles$589$436+35.1%$1,368$1,280+6.9%$1,743
TOTAL BENEFITS AND EXPENSES$71,287$67,170+6.1%$206,415$195,573+5.5%$265,700
Income from operations$2,396$2,578-7.1%$7,430$6,855+8.4%$9,200
Interest expense and other$(333)$(347)-4.0%$(1,046)$(1,046)0.0%$(1,408)
Gain on sale of businesses—$38-100.0%$17$79-78.5%$13
Net investment gains$36$26+38.5%$225$76+196.1%$(24)
Income before income taxes$2,099$2,295-8.5%$6,626$5,964+11.1%$7,781
Total income taxes$401$322+24.5%$1,192$950+25.5%$1,493
Net income$1,698$1,973-13.9%$5,434$5,014+8.4%$6,288
Less: Net income attributable to NCI$256$105+143.8%$678$291+133.0%$331
SHAREHOLDERS’ NET INCOME$1,442$1,868-22.8%$4,756$4,723+0.7%$5,957
Basic EPS$5.49$7.02-21.8%$18.09$17.65+2.5%$22.33
Diluted EPS$5.47$6.98-21.6%$18.02$17.52+2.9%$22.18

Note: FY2025 (Dec-2025) comparative line items for Pharmacy revenues, Premiums, and Fees are derived from the FY2025 10-K page 58 to provide a complete full-year position.


8.2. Nine-Month Performance Summary at a Glance

Based on the image provided, here is the definitive at-a-glance table for your webpage publication, strictly adhering to the 9M 2026 vs 9M 2025 comparison with the FY2025 year-end position.

Line Item9M 20269M 2025Change ($)Change (%)
Total Revenues$213,845$202,428+$11,417+5.6%
Pharmacy and other service costs$169,393$157,196+$12,197+7.8%
Medical costs and other benefit expenses$24,850$26,089-$1,239-4.7%
SG&A$10,804$11,008-$204-1.9%
Income from Operations$7,430$6,855+$575+8.4%
Income before income taxes$6,626$5,964+$662+11.1%
Net Income (Shareholders)$4,756$4,723+$33+0.7%
Diluted EPS$18.02$17.52+$0.50+2.9%

Key Observation: While 9M operating income grew 8.4% due to SG&A discipline, the standalone Q3 2026 was a bloodbath. Q3 Operating Income fell 7.1%, and Net Income fell 22.8%. The 9M net income looks flat only because Q1 and Q2 carried the weight.


Crucial Analytical Takeaways

  1. The Operating Profit: 9M Operating Profit grew 8.4% to $7.43 billion**, driven by strict SG&A control (down 1.9% to $10.8B). However, the Q3 standalone Operating Profit fell 7.1% to $2.39B, indicating that Q1 and Q2 of 2026 carried the heavy lifting, while Q3 faced severe margin compression.
  2. The Q3 Profit Collapse: Q3 2026 Shareholders’ Net Income fell 22.8% to $1.442 billion. This was driven by a massive spike in **Medical costs (+8.3%)** which significantly outpaced Premium growth (+8.9% but on a smaller base), combined with an $256M payout to Noncontrolling Interests (up from just $105M in Q3 2025).
  3. Premiums vs. Pharmacy: The structural shift is undeniable. In 9M 2026, Pharmacy revenues grew 7.5%, while Premiums declined 4.6%. The company is increasingly an Evernorth (PBM/Pharmacy) story rather than a traditional health insurer.
  4. Tax Rate Spiked: Total income taxes rose 25.5% in 9M 2026 despite pre-tax income only rising 11.1%. The effective tax rate in Q3 2026 was 19.1% (up from 14.0% in Q3 2025), eating into bottom-line profits.

Key Observation: While 9M operating income grew 8.4% due to SG&A discipline, the standalone Q3 2026 deteriorated sharply. Q3 Operating Income fell 7.1% and Net Income fell 22.8%. The 9M net income appears flat only because Q1 and Q2 carried the weight. On an adjusted basis, Q3 EPS of $7.98 exceeded consensus, and management raised FY2026 adjusted EPS guidance to at least $30.60 .

8.3 Ratio Analysis vs. U.S. Industry Average

Ratio CategoryMetricCigna (Q3 2026)U.S. Industry AvgAssessment
LiquidityCurrent Ratio0.84x~1.15xBelow average; typical for PBM model
Quick Ratio0.69x~0.90xRelies on rapid claims turnaround
LeverageDebt-to-Equity0.72x~0.85xConservative leverage
Debt-to-Capital41.8%~45.0%Healthy; on target for ~40%
EfficiencyReceivables (Days)39.7 days~25 daysSlower collections; needs monitoring
Inventory (Days)8.8 days~15 daysHighly efficient pharma turnover
Payables (Days)16.1 days~30 daysPays suppliers quickly
ProfitabilityOperating Margin3.5%~12.0%Structurally low due to PBM gross-up
ROE15.65% (Dashboard)~19.5%Below sector but improving
ROIC11.34% (Dashboard)~19.5%Below sector average

Dashboard Cross-Reference: The Capital Insight BD Dashboard reports a PE Ratio of 13.23x (97.9th percentile of its historical range) and a Forward PE of 9.01x, suggesting the market is pricing in near-term earnings compression but expects recovery. The PEG ratio of 0.75 indicates undervaluation relative to growth expectations. Sector relative PE is -71.08% versus Health Care peers, reflecting Cigna’s structurally lower multiple due to its PBM-heavy revenue mix (Source: Capital Insight BD Dashboard).


9. Opportunities and Threats (Investor Perspective)

Opportunities

  1. Specialty Pharmacy Growth: Evernorth’s Accredo and EnGuide Pharmacy (focused on GLP-1 drugs) are capturing high-margin specialty drug spend. Specialty and Care Services delivered 15% pretax adjusted earnings growth in Q3 2026, and management expects 8–12% long-term growth .
  2. Transparent Rebate Model (“Signature”): Cigna is shifting to a rebate-free model, with Cigna Healthcare fully insured book adopting it on January 1, 2027, and broader ramp through 2028. This could reduce regulatory scrutiny and improve client retention.
  3. Capital Returns & Buybacks: Management reiterated that share repurchase remains an attractive use of capital, with greater flexibility expected in 2027 as the debt-to-capital target of ~40% is achieved.
  4. 2027 EPS Growth Guidance: Management expects at least 10% adjusted EPS growth in 2027 off the 2026 run-rate of approximately $30, driven by Cigna Healthcare growth and Evernorth’s low-single-digit growth .

Threats

  1. Medical Cost Inflation: Q3 2026 MCR was 85.0%. Full-year MCR guidance is maintained at 84.2% ± 25 basis points. If medical costs continue to outpace premiums, Cigna Healthcare margins will remain compressed.
  2. Working Capital Squeeze: The $2.77B AR build in 9M 2026 is a cash conversion concern.
  3. PBM Transitional Headwinds: Management explicitly stated that 2026 and 2027 are “transitional years” for Pharmacy Benefit Services, with income expected to decline single digits in 2027 due to gross rebate pool compression and lower employer coverage of GLP-1s for weight management .
  4. ACA Exchange Exit: Cigna is exiting the ACA exchange market, expected to create an all-in headwind of approximately $200 million in 2027.
  5. AI Litigation: Lawsuits regarding the use of AI in claims evaluation pose a novel legal and reputational risk.

10. Investments in Other Company Shares

Source: Note 11

Cigna significantly increased its Equity Securities portfolio from $561M (Dec 2024) to **$3.556 billion** (Dec 2025). This $3.0 billion surge reflects strategic investments funded by the HCSC divestiture. Because these are marked-to-market, a **10% decline** in these holdings would result in a **~$355M pretax hit** (~$1.32 EPS impact).


11. Other Important Issues

Shareholding Structure (Dashboard Data): Institutional investors hold approximately 42.69% of shares, led by BlackRock (8.89%), Vanguard (6.55%), and State Street (4.81%). Insiders hold only 0.36%, with CEO David Cordani holding the largest individual stake at 0.25%. The high institutional ownership suggests stability but also means the stock is sensitive to institutional rotation (Source: Capital Insight BD Dashboard).

AOCI Deterioration: Cigna’s Accumulated Other Comprehensive Loss deepened to **-$4.47 billion** in Q3 2026 from -$2.8 billion at YE2025, signaling unrealized losses in the debt securities portfolio, likely due to elevated interest rates.



12. Fiscal Year 2026 and Next Quarter Projections (Bear / Base / Bull)

Methodology: Projections are anchored to management’s Q3 2026 guidance (FY2026 adjusted EPS ≥ $30.60; FY2026 MCR midpoint 84.2%; FY2026 Evernorth pretax earnings ≥ $6.9B; Cigna Healthcare pretax earnings ≥ $4.6B) , S&P Global analyst consensus (25 analysts; average price target $344.04; range $304–$400) , and management’s 2027 early outlook of at least 10% adjusted EPS growth off the ~$30 run-rate . Revenue estimates incorporate 9M 2026 actuals ($213.8B) plus Q4 run-rate assumptions.

FY2026 Full-Year Projection

Key Assumptions:

Bear Case: MCR exceeds 85.5% in Q4; PBM rebate compression accelerates; ACA exit costs front-loaded; multiple compresses to ~9x forward PE

Base Case : Management guidance met; MCR at 84.2% midpoint; Evernorth $6.9B; Cigna Healthcare $4.6B; multiple of ~10.8x forward PE

Bull Case : MCR below 83.5%; Specialty pharmacy outperforms; buyback acceleration in Q4; multiple expands to ~11.7x forward PE

ScenarioFY2026 RevenueFY2026 Net Income (Shareholders)FY2026 Diluted EPSTarget Stock Price (12M)
Bear Case$282.0B$5.80B$29.50$270
Base Case$285.0B$6.10B$30.60$330
Bull Case$288.0B$6.35B$31.50$370

Q4 2026 Standalone Projection

ScenarioQ4 2026 RevenueQ4 2026 Diluted EPSBasis
Bear$68.0B$7.20MCR deterioration; year-end true-ups
Base$71.2B$7.42Consensus estimate
Bull$73.0B$7.65Strong Specialty & Care; favorable prior-year development

Third-Party Analyst Consensus (for reference)

  • Consensus Rating: Buy (12 Strong Buy, 5 Buy, 7 Hold, 0 Sell)
  • Average 12-Month Price Target: **$344.04** (range $304–$400)
  • Recent Analyst Actions (Nov 2026):
    • Jefferies: Hold, target raised to **$304** (from $288)
    • Piper Sandler: Buy, target **$360** (from $370)
    • Bernstein: Buy, target **$390** (from $387)
    • Wells Fargo: Hold, target **$325** (from $307)

Management 2027 Early Outlook: At least 10% adjusted EPS growth off the 2026 run-rate of ~$30, implying **≥$33.00** .


13. PDF Reference Page Numbers

  • Business Overview: 10-K Page 4
  • Income Statement: 10-Q Page 3 (provided image)
  • Balance Sheet: 10-Q Pages 4–5 (provided image)
  • Cash Flow Statement: 10-Q Pages 6–7 (provided image)
  • Audit Report (PwC): 10-K Pages 53–55
  • Note 11 (Investments): 10-K Notes
  • Legal Matters: 10-K Note D

14. Sources

  • The Cigna Group FY2025 Form 10-K (filed Feb 26, 2026)
  • The Cigna Group Q3 2026 Form 10-Q (unaudited)
  • Q3 2026 Earnings Call Transcript, November 4, 2026
  • PwC Auditor’s Report included in 10-K
  • ReadyRatios/CSIMarket (SIC 6321 Industry Averages)
  • Capital Insight BD Master Dashboard (Market Snapshot, PE/PEG/Forward PE, Sector Comparison, Shareholding Movement, Composite Scores, Period Return/Volatility)
  • S&P Global / Stock Analysis (Analyst Consensus, Price Targets, Ratings)
  • Yahoo Finance (Forward PE, PEG Ratio, Analyst Estimates)
  • Reuters (November 5, 2026) – Guidance update
  • Business Insider / Jefferies (November 12, 2026) – Price target revision

15. Disclaimer

This report has been prepared by CapitalinsightBD for informational purposes only. It does not constitute an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities. The analysis is based on publicly available information believed to be reliable but not guaranteed for accuracy or completeness. Financial figures are derived from company filings and third-party sources; errors in extraction or conversion are possible. Industry benchmark comparisons are inherently imperfect due to differences in business mix and accounting methodologies. Scenario projections are estimates, not guarantees of future performance. Readers should conduct their own due diligence and consult with qualified financial advisors before making any investment decisions. CapitalinsightBD and its staff accept no liability for any loss arising from reliance on this report.


Md Kollol Hossain
CEO, CapitalinsightBD
info@capitalinsightbd.com